Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications

Barchart · 3d ago

TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer

Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responses

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.